Friday, Bristol Myers Squibb & Co (NYSE:BMY) posted second-quarter revenues of $12.20 billion, beating the consensus of $11.55 billion, an increase of 9% year-over-year, or 11% when adjusted for foreign exchange impacts, primarily driven by the Growth Portfolio and Eliquis.
Growth Portfolio worldwide revenues increased to $5.6 billion compared with $4.7 billion a yr ago, representing growth of 18% on a reported basis or 21% when adjusted for foreign exchange impacts.
Growth Portfolio revenues were primarily driven by higher demand for Opdivo, Reblozyl, Camzyos, and Opdualag, partially offset by Abecma.
Opdivo sales incresaed 11% to $2.39 billion. Abecma sales fell 28% to $95 million.
Revenues for the Legacy Portfolio inside the second quarter were $6.6 billion compared with $6.5 billion a yr ago, representing growth of two% on a reported basis, or 3% when adjusted for foreign exchange impacts.
Legacy Portfolio revenues were driven by higher demand for Eliquis and Pomalyst, partially offset by a decline in Revlimid due to generic erosion. Eliquis sales were up 7% to $3.42 billion.
The company reported an adjusted EPS of $2.07, compared with an income of $1.75 a yr ago, beating the consensus of $1.63.
“Our second quarter results reflect progress against our technique to position BMS for long-term, sustainable growth. As we move into the second half of the yr, we remain focused on prioritizing opportunities with the most effective growth potential and impact for patients, including the anticipated U.S. launch of KarXT. We’re also driving operational excellence throughout the company, becoming more agile and strengthening execution,” said Christopher Boerner, board chair and CEO.
Guidance: Bristol Myers Squibb revises 2024 adjusted EPS guidance to $0.60-$0.90 versus prior guidance of $0.40-$0.70 and consensus Of $0.51.
For 2024, the U.S. drug maker expects revenue growth to be on the upper end of the previously provided low single-digit range.
Price Motion: BMY stock is up 5.17% at $47.61 through the premarket session on the last check on Friday.
Read Next:
Photo via Shutterstock
“ACTIVE INVESTORS’ SECRET WEAPON” Supercharge Your Stock Market Game with the #1 “news & the whole thing else” trading tool: Benzinga Pro – Click here to begin out Your 14-Day Trial Now!
Get probably the most recent stock evaluation from Benzinga?
This text Bristol Myers Squibb Witnesses Strong Demand For ‘Newer Drugs’ As Q2 Earnings Beat Expectations, Raises 2024 Profit Forecast originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga doesn’t provide investment advice. All rights reserved.